Agilix Corp.
This article was originally published in Start Up
Executive Summary
Mid-stage clinical trial data rarely provide an easy answer on whether to advance a compound into complex and costly pivotal studies. Agilix Corp. has stepped into that void to offer gene expression analysis services using its GenCompass-a microarry-based expression profiling system that provides a rapid whole genome comparison between test and control subjects, providing data even about as yet uncharacterized genes.
You may also be interested in...
Microarrays Aim for Center Stage
Accepted in discovery, microarrays are paving the way for biomarker development and eventually, molecular diagnostics.
Biosite: Building a Solid Franchise
Biosite is one of a few diagnostic companies that has had to grapple with a literal run on its product--a point-of-care proprietary cardiovascular test that took off in the marketplace almost immediately after it was introduced in 2000. Now, it faces two challenges: the advent of competition from large in-vitro diagnostic companies and following up with a seond act as its explosive growth slows to more normal levels.
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.